Harbour BioMed Reports Seventh Consecutive Profitable Half-Year, Driven by Strategic Collaborations and AI-Enabled Pipeline Advances
核心洞察
Harbour BioMed (搜索) expects H1 2026 revenue between US$120–125 million, a 19–24% increase year-over-year, with profit ranging from US$62–67 million.
Strategic collaborations with Bristol Myers Squibb (搜索), AstraZeneca, and Solstice Oncology (搜索) contributed significantly, including a BMS deal worth up to $1.035 billion in milestones.
The company's AI-powered Hu-mAtrIx™ platform achieved a 78.5% target hit rate for heavy-chain-only antibody generation, and a joint venture with BioMap (搜索) was formed to advance AI-enabled drug discovery.
Harbour BioMed (搜索) (HKEX: 02142), a global biopharmaceutical company with operations in Cambridge, Mass., Rotterdam, and Shanghai, announced a positive profit alert for the six months ended June 30, 2026, marking its seventh consecutive profitable half-year. The company expects revenue between US$120 million and US$125 million, representing an increase of approximately 19% to 24% compared with approximately US$101 million for the same period in 2025. Profit is projected to range between US$62 million and US$67 million, with total adjusted profit between US$70 million and US$75 million.
Dr. Jingsong Wang, Founder, Chairman and CEO of Harbour BioMed (搜索), stated: "Our expected profitability in the first half of 2026 marks an important milestone in Harbour BioMed's development and strongly validates our differentiated business model. The value of our proprietary technology platforms is gaining recognition through a growing number of deep strategic partnerships with multinational pharmaceutical companies and leading global biotechnology companies."
Strategic Collaborations Drive Revenue Growth
The company's revenue growth was fueled by the continued execution of high-value strategic collaborations. In December 2025, Harbour BioMed (搜索) entered into a long-term global strategic collaboration with Bristol Myers Squibb (搜索) to jointly discover and develop next-generation multi-specific antibodies. Under the agreement, Harbour BioMed could receive payments totaling $90 million, plus development and commercial milestones of up to $1.035 billion.
The company also expanded its strategic collaboration with AstraZeneca to include antibody-drug conjugates (ADCs) and T-cell engager (TCE) therapeutics, building on a potential 10-year long-term partnership. Previously announced licensing partnerships with Otsuka, Pfizer, Windward Bio, and others continued to generate meaningful revenue. To date, Harbour BioMed (搜索)'s proprietary technology platforms have been applied across more than 380 drug discovery programs spanning multiple therapeutic areas, with more than 20 molecules advancing into IND-enabling studies or clinical development.
Nona Biosciences (搜索), a subsidiary of Harbour BioMed (搜索), has entered a period of rapid growth, with revenue from platform-based technology licensing and discovery services becoming another important business pillar. This includes a platform collaboration with Lonza focused on central nervous system applications.
AI Integration and Platform Innovation
Harbour BioMed (搜索) has positioned artificial intelligence as a core strategic priority. In October 2025, the company launched the first fully human AI-powered heavy-chain-only antibody (HCAb) generation and screening model enabled by its proprietary Hu-mAtrIx™ AI platform, achieving a target hit rate of 78.5%. The same month, Harbour BioMed initiated the AI + Biopharmaceutical Ecosystem Alliance, bringing together organizations including Insilico Medicine and Molecule Mind.
In May 2026, the company reported encouraging preclinical data for LET003 (搜索), its first next-generation ACVR2A/2B (搜索)-targeting monoclonal antibody developed using the Hu-mAtrIx™ AI platform. In June 2026, Harbour BioMed (搜索) entered into a comprehensive long-term strategic partnership with BioMap (搜索), establishing MegaStream TechBio, a joint venture dedicated to developing AI-enabled drug pipelines for the global market.
Clinical Pipeline Progress
Harbour BioMed (搜索) now has nearly 30 innovative product candidates across immunology, oncology, obesity and metabolic diseases, and CNS disorders. Key clinical developments include:
Batoclimab, the company's anti-FcRn (搜索) monoclonal antibody, has become the first drug in China to complete the full clinical development pathway from Phase 1 through pivotal trials, with a biologics license application (BLA) submitted for multiple autoimmune diseases.
HBM9378, an ultra-long-acting anti-TSLP (搜索) antibody, demonstrated a substantially extended half-life in Phase 1 data, supporting twice-yearly dosing. Initial Phase 2 data in asthma (搜索) are expected in the second half of 2026, and the Phase 2 SIRIUS study in chronic obstructive pulmonary disease (搜索) (COPD) has dosed its first patients. HBM7575 (搜索), a TSLP-targeting bispecific antibody, has dosed the first subject in a Phase 1 study for atopic dermatitis (搜索) and received IND clearance for asthma.
In immuno-oncology, HBM4003, an anti-CTLA-4 (搜索) heavy-chain-only antibody, achieved an objective response rate (ORR) of 34.8% and a median progression-free survival (mPFS) of 4.2 months in a Phase 2 study in microsatellite stable (MSS) metastatic colorectal cancer (搜索) (mCRC) when combined with tislelizumab. Based on these results, the company entered into a licensing agreement and equity partnership with Solstice Oncology (搜索) in February 2026, receiving upfront consideration valued at over $105 million with potential milestone payments of up to approximately $1.1 billion.
Additionally, HBM7004, a bispecific antibody for solid tumors, has received IND clearance from the U.S. FDA, while its IND application has been accepted by China's NMPA.
With seven consecutive profitable half-years, Harbour BioMed (搜索) stated it has officially entered a phase of "normalized profitability," validating the sustainability of its platform-based business model. The company noted that all figures are based on unaudited management accounts and actual results may differ.